The present invention relates to formulations comprising a therapeutically
effective amount of pravastatin, or a pharmaceutically acceptable salt
thereof, and methods of their use. The present formulations and methods
are designed to release little or no pravastatin in the stomach but
release a therapeutic amount of pravastatin in the small intestine,
thereby limiting systemic exposure of the body to pravastatin and
maximizing hepatic-specific absorption of the drug. The formulations and
methods of the present invention are particularly useful for treating
and/or preventing conditions that are benefited by decreasing levels of
lipids and/or cholesterol in the body.